International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-2 doi: 10.5281/zenodo.7857874
Original Article
Relationship between C-Reactive Protein and Stages of Chronic Obstructive Pulmonary Disease; A Cross-Sectional Study
 ,
 ,
Published
April 24, 2023
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is an inflammatory lung disease that obstructs airflow. Here, we evaluate the relationship between C-reactive protein (CRP) levels and the stages of COPD. Methods: A cross-sectional study involving 60 patients diagnosed with COPD aged between 35 to 70 years was performed, and the relationship between CRP and stages of COPD was noted. Data was tabulated and analyzed using Analysis of Variance (ANOVA), and a p-value of <0.05 was considered significant. Results: Fifty percent of the study participants were aged between 51 to 60 years, with a mean of 55.85 ± 7.64 years. According to the Global Initiative for Lung Disease (GOLD) criteria, 50 percent of the study participants were diagnosed with Stage II COPD and 35% with Stage III COPD. The mean forced expiratory volume in one second (FEV1) was 84 ±2.39 percent in stage I COPD and 28.20 ±1.48 percent in stage IV. The mean CRP levels recorded were 3.91 ±1.26 mg/dL in stage I COPD (p<0.05), 5.79 ±1.23 mg/dL in stage II (p<0.05), 9.01 ±0.96 mg/dL in stage III (p<0.05) and 11.98 ±0.73 stage IV (p<0.05). Statistically significant incremental mean CRP level was noted with progressive stages of COPD. Conclusions: COPD is a systemic inflammatory disease in which CRP levels significantly increase with the progression of the disease. This warrants serial measurement of CRP in patients with COPD to monitor the progression of the disease. In addition, the measurement of CRP should also be considered in stable COPD patients to document the baseline for follow-up.
Recommended Articles
Loading Image...
Volume-4, Issue-2
Citations
1951 Views
152 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved